作者
Nitin Jain,Michael J. Keating,Philip A. Thompson,Alessandra Ferrajoli,Jan A. Burger,Gautam Borthakur,Koichi Takahashi,Zeev Estrov,Nathan Fowler,Tapan M. Kadia,Marina Konopleva,Yesid Alvarado,Musa Yılmaz,Courtney D. DiNardo,Prithviraj Bose,Maro Ohanian,Naveen Pemmaraju,Elias Jabbour,Koji Sasaki,Rashmi Kanagal‐Shamanna,Keyur P. Patel,Jeffrey L. Jorgensen,Naveen Garg,Xuemei Wang,Katrina Sondermann,Nichole Cruz,Chongjuan Wei,Ana Ayala,William Plunkett,Hagop M. Kantarjian,Varsha Gandhi,William G. Wierda
摘要
Ibrutinib, an inhibitor of Bruton’s tyrosine kinase, and venetoclax, an inhibitor of B-cell lymphoma 2 protein, have been approved for patients with chronic lymphocytic leukemia (CLL). Preclinical investigations have indicated potential synergistic interaction of their combination.
PDF的下载单位、IP信息已删除
(2025-6-4)
无极微光
舜瞬
蓝天
LaTeXer
科研狗
pluto
Moonpie
zp560
乐空思
潇洒的惋清
干净的琦
淡然的新晴
科研girl
XXXAAA
Rainyin
Guo
殷勤的紫槐
淡然冬灵
学术文献互助
lizishu
皖公网安备34019202002308
